Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikki Burdett

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Internal Medicine Journal|October 12, 2019
Bevacizumab prescribing practices for epithelial ovarian cancer in AustraliaNikki Burdett, Ganessan Kichenadasse
The Medical Journal of Australia|October 2, 2024
Planetary care is good cancer careNikki Burdett, Ben Dunne
ESMO Open|September 16, 2020
New biomarkers for checkpoint inhibitor therapyNikki Burdett, Jayesh Desai
International Journal of Evidence-Based Healthcare|August 29, 2012
Difficulties with assessing the benefit of glucosamine sulphate as a treatment for osteoarthritisNikki Burdett, Julian David McNeil
Journal of the National Cancer Institute|July 17, 2018
Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology TrialsNikki Burdett, Andrew D Vincent, Michael O'Callaghan, et al.
Thoracic Cancer|April 4, 2017
Video-assisted thoracoscopy in the management of intrapleural extravasation of cytotoxic chemotherapyVictor J Aguirre, Dylan Barnett, Nikki Burdett, et al.
Asia-Pacific Journal of Clinical Oncology|June 20, 2019
Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapyNikki Burdett, Kristin Hsu, Libo Xiong, et al.
Histopathology|March 31, 2023
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programmeHeather Thorne, Lisa Devereux, Jason Li, et al.
Nature Reviews. Cancer|April 13, 2026
Rethinking ovarian cancer III: the past decade and future directionsFrances R Balkwill, Céline M Laumont, Nikki Burdett, et al.
JAMA Oncology|June 25, 2026
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsLucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Internal Medicine Journal|October 12, 2019
Bevacizumab prescribing practices for epithelial ovarian cancer in AustraliaNikki Burdett, Ganessan Kichenadasse
The Medical Journal of Australia|October 2, 2024
Planetary care is good cancer careNikki Burdett, Ben Dunne
ESMO Open|September 16, 2020
New biomarkers for checkpoint inhibitor therapyNikki Burdett, Jayesh Desai
International Journal of Evidence-Based Healthcare|August 29, 2012
Difficulties with assessing the benefit of glucosamine sulphate as a treatment for osteoarthritisNikki Burdett, Julian David McNeil
Journal of the National Cancer Institute|July 17, 2018
Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology TrialsNikki Burdett, Andrew D Vincent, Michael O'Callaghan, et al.
Thoracic Cancer|April 4, 2017
Video-assisted thoracoscopy in the management of intrapleural extravasation of cytotoxic chemotherapyVictor J Aguirre, Dylan Barnett, Nikki Burdett, et al.
Asia-Pacific Journal of Clinical Oncology|June 20, 2019
Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapyNikki Burdett, Kristin Hsu, Libo Xiong, et al.
Histopathology|March 31, 2023
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programmeHeather Thorne, Lisa Devereux, Jason Li, et al.
Nature Reviews. Cancer|April 13, 2026
Rethinking ovarian cancer III: the past decade and future directionsFrances R Balkwill, Céline M Laumont, Nikki Burdett, et al.
JAMA Oncology|June 25, 2026
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsLucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, et al.
Pageof 1